Some Troubling Numbers For Big Pharma Consolidation
A recent CenterWatch Inc. study of 11 major pharmaceutical company mergers suggests that the downturn in sales and marketing figures for consolidated firms is accompanied by decreased R&D output.
You may also be interested in...
Despite the increasingly common perception of the helpless mega-merged giant, vastly increased scale can provide such companies with significant competitive advantages, from which companies were unwilling or unable to benefit in the past. The largest companies, structured properly, should be able to discover disproportionately more compounds; develop them faster; and market them more successfully. But to reap these benefits, the super heavyweight pharmas will, paradoxically, have to learn how to think small.
C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.